Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Sell
48
PSTX Quote, Financials, Valuation and Earnings
Last price:
$9.48
Seasonality move
:
-14.94%
Day range:
$9.45 - $9.50
52-week range:
$1.87 - $9.58
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
6.09x
P/B ratio:
10.61x
Volume:
442.2K
Avg. volume:
2M
1-year change:
182.44%
Market cap:
$924.9M
Revenue:
$64.7M
EPS (TTM):
-$0.62
Analysts' Opinion
-
Consensus RatingPoseida Therapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $14.00, Poseida Therapeutics has an estimated upside of 0.11% from its current price of $9.49.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $10.00 representing 100% downside risk from its current price of $9.49.
Fair Value
-
According to the consensus of 3 analysts, Poseida Therapeutics has 0.11% upside to fair value with a price target of $14.00 per share.
PSTX vs. S&P 500
-
Over the past 5 trading days, Poseida Therapeutics has underperformed the S&P 500 by -2.97% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Poseida Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Poseida Therapeutics has grown year-over-year revenues for 4 quarters straight. In the most recent quarter Poseida Therapeutics reported revenues of $71.7M.
Earnings Growth
-
Poseida Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Poseida Therapeutics reported earnings per share of $0.21.
Enterprise value:
753M
EV / Invested capital:
5.15x
Price / LTM sales:
6.09x
EV / EBIT:
--
EV / Revenue:
4.99x
PEG ratio (5yr expected):
-0.01x
EV / Free cash flow:
-43.97x
Price / Operating cash flow:
1,229.95x
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-21.23%
Net Income Margin (TTM):
-40.28%
Return On Equity:
-66.05%
Return On Invested Capital:
-40.32%
Operating Margin:
27.52%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $151.7M | $49.8M | $150.9M | $9.4M | $71.7M | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$44.2M | -$136.8M | -$62.5M | -$36.2M | $19.7M | |
| EBITDA | -$18.7M | -$117.1M | -$46.2M | -$28M | $23.9M | |
| Diluted EPS | -$0.68 | -$1.51 | -$0.62 | -$0.35 | $0.21 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $347.3M | $204.8M | $325.1M | $252.7M | $250.7M | |
| Total Assets | $405.2M | $261.9M | $380.5M | $302.3M | $293.6M | |
| Current Liabilities | $29.8M | $31.8M | $49M | $77M | $78.3M | |
| Total Liabilities | $109.3M | $111.8M | $164.2M | $178.6M | $206.4M | |
| Total Equity | $295.8M | $150.2M | $216.3M | $123.7M | $87.2M | |
| Total Debt | -- | -- | $58.2M | $58.5M | $58.9M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$20.7M | -$61M | -$15M | $7.9M | -$9.6M | |
| Cash From Investing | -$117.6M | -$94.5M | $38.2M | -$47.2M | $27.6M | |
| Cash From Financing | $105.3M | $16.2M | $699K | $14.9M | $742K | |
| Free Cash Flow | -$24.6M | -$64M | -$17.1M | $7.1M | -$10.2M | |
PSTX
Sector
Market Cap
$924.9M
$46.1M
Price % of 52-Week High
99.06%
46.02%
Dividend Yield
0%
0%
Shareholder Yield
-0.04%
-0.6%
1-Year Price Total Return
182.44%
-30.52%
Beta (5-Year)
--
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$9.48
200-day SMA
Buy
Level
$3.54
Bollinger Bands (100)
Buy
Level
1.5 - 6.8
Chaikin Money Flow
Sell
Level
-38.5M
20-day SMA
Buy
Level
$9.42
Relative Strength Index (RSI14)
Buy
Level
86.28
ADX Line
Sell
Level
16.72
Williams %R
Neutral
Level
-36
50-day SMA
Buy
Level
$5.40
MACD (12, 26)
Buy
Level
1.20
25-day Aroon Oscillator
Buy
Level
60
On Balance Volume
Neutral
Level
50M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-2.3703)
Sell
CA Score
(Annual)
Level (-2.1948)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (8)
Sell
Ohlson Score
Level (3.0957)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Poseida Therapeutics Inc is a clinical-stage biopharmaceutical company focused on leveraging non-viral gene engineering technologies to create life-saving therapeutics for patients with a high unmet medical need. It has built a pipeline of autologous and allogeneic chimeric antigen receptor T cell, or CAR-T, product candidates, initially focused on the treatment of hematological malignancies and solid tumours.
Stock Forecast FAQ
In the current month, PSTX has received 3 Buy ratings 0 Hold ratings, and 0 Sell ratings. The PSTX average analyst price target in the past 3 months is $14.00.
-
Where Will Poseida Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Poseida Therapeutics share price will rise to $14.00 per share over the next 12 months.
-
What Do Analysts Say About Poseida Therapeutics?
Analysts are divided on their view about Poseida Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Poseida Therapeutics is a Sell and believe this share price will drop from its current level to $10.00.
-
What Is Poseida Therapeutics's Price Target?
The price target for Poseida Therapeutics over the next 1-year time period is forecast to be $14.00 according to 3 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is PSTX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Poseida Therapeutics is a Buy. 3 of 3 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of PSTX?
You can purchase shares of Poseida Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Poseida Therapeutics shares.
-
What Is The Poseida Therapeutics Share Price Today?
Poseida Therapeutics was last trading at $9.48 per share. This represents the most recent stock quote for Poseida Therapeutics. Yesterday, Poseida Therapeutics closed at $9.49 per share.
-
How To Buy Poseida Therapeutics Stock Online?
In order to purchase Poseida Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
87
PSIX alert for Dec 25
Power Solutions International [PSIX] is up 27.42% over the past day.
Buy
65
TSLL alert for Dec 25
Direxion Daily TSLA Bull 2X Shares [TSLL] is up 19.46% over the past day.
Buy
75
SMLR alert for Dec 25
Semler Scientific [SMLR] is up 15.37% over the past day.
